Aura Biosciences (AURA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO and President, with formal business outlined as per the notice and proxy statement.
The meeting was held virtually, with stockholders able to participate and submit questions through an online portal.
Officers, directors, and representatives from the audit firm were introduced.
Board and executive committee updates
Two nominees, David Johnson and Teresa Marie Bitetti, were presented for election as Class 2 directors for a three-year term.
No stockholder nominations for directors were received in advance.
Corporate governance
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was submitted for ratification.
The audit committee, composed entirely of independent directors, selected the audit firm.
Stockholder ratification of the auditor was sought as a matter of good governance, though not required by bylaws.
Latest events from Aura Biosciences
- Biotech firm seeks to raise up to $500M for R&D and growth, with $200M via Jefferies at-the-market.AURA
Registration filing - Bel-sar shows strong efficacy and safety as a potential first curative therapy for early choroidal melanoma.AURA
Corporate presentation - Q2 net loss widened to $45.6M; Phase 3 trial fully enrolled, cash runway to 1H 2029.AURA
Q2 2026 - Shareholders approved all proposals, including a major increase in authorized common stock.AURA
EGM 2026 - Vote sought to expand authorized shares and amend equity plan for future growth and flexibility.AURA
Proxy filing - Vote to expand authorized shares and amend the equity plan to support growth and retention.AURA
Proxy filing - Pivotal trials advance in ocular and bladder cancer, targeting large markets with vision-preserving therapies.AURA
TD Cowen 46th Annual Health Care Conference - Bel-sar achieved 80% tumor control and 90% vision preservation, advancing to Phase 3.AURA
Status Update - Bel-sar's dual-action therapy shows strong early efficacy and safety, supporting a shift in bladder cancer care.AURA
Status Update